Related trials
		 
			
				 
				
					BASKET-PROVE (SES), 2010 - sirolimus eluting stent  vs bare-metal stent
				
			 
			
				 
				
					GISSOC II, 2010 - sirolimus eluting stent  vs bare-metal stent
				
			 
			
				 
				
					RESOLUTE All comers, 2010 - zotarolimus eluting stent  vs everolimus eluting stent
				
			 
			
				 
				
					SORT-OUT-3, 2010 - zotarolimus eluting stent  vs sirolimus eluting stent
				
			 
			
				 
				
					SPIRIT IV, 2010 - everolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					BASKET-PROVE (EES), 2010 - everolimus eluting stent  vs bare-metal stent
				
			 
			
				 
				
					ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent  vs zotarolimus eluting stent
				
			 
			
				 
				
					Thiele, 2009 - sirolimus ES  vs MIDCAB
				
			 
			
				 
				
					ENDEAVOR IV, 2009 - zotarolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					ZEST AMI (vs PES), 2009 - zotarolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					COMPARE, 2009 - everolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent  vs sirolimus eluting stent
				
			 
			
				 
				
					ZEST (vs PES), 2009 - zotarolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					ZEST (vs SES), 2009 - zotarolimus eluting stent  vs sirolimus eluting stent
				
			 
			
				 
				
					ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer  vs sirolimus eluting stent
				
			 
			
				 
				
					ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer  vs sirolimus eluting stent
				
			 
			
				 
				
					GENIUS-STEMI, 2009 - Genous stent  vs bare-metal stent
				
			 
			
				 
				
					SYNTAX, 2009 - paclitaxel eluting stent  vs CABG
				
			 
			
				 
				
					PASEO, 2009 - drug-eluting stents  vs bare-metal stent
				
			 
			
				 
				
					ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent  vs sirolimus eluting stent
				
			 
			
				 
				
					DEBATER (SES vs BMS), 2009 - sirolimus eluting stent  vs bare-metal stent
				
			 
			
				 
				
					ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					ZEST AMI (vs SES), 2009 - zotarolimus eluting stent  vs sirolimus eluting stent
				
			 
			
				 
				
					SORT OUT II, 2008 - sirolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					DES-DIABETES, 2008 - sirolimus eluting stent  vs paclitaxel eluting stent
				
			 
		 
		 
		 
		
		See also:
		 
			
				
					All coronary artery disease clinical trials
				
			
		
			
			All clinical trials of Drug eluting stent 
			
		
		
			
			All clinical trials of Genous stent 
			
		
	 | 
	
		 
	 | 
	
	Treatments
	
	
		| Studied treatment | 
		
		endothelial progenitor cell capture stent
		 
		
		
		 | 
	 
	
		| Control treatment | 
		
		cobalt chromium stent
		 
		
		
		 | 
	 
		
			| Concomittant treatment | 
			dual antiplatelet therapy for 30 days | 
		 
	 
	
	
	
	Patients
	
		
			| Patients | 
			patients with ST-elevation myocardial infarction | 
		 
				| Baseline characteristics | 
					
					
						
							| age | 
							57 y  | 
						 
						
							| diabetes (%) | 
							29%  | 
						 
						
							| Female (%) | 
							21%  | 
						 
						
							| STEMI | 
							100%  | 
						 
					 						
					 | 
				 
	 
	
	
	
	
	
	
	Method and design
	
	
		| Randomized effectives | 
		50 / 50 (studied vs. control) | 
	 
		
			| Design | 
			Parallel groups | 
		 
		
			| Blinding | 
			NA | 
		 
		
			| Follow-up duration | 
			6 months | 
		 
		
			| Primary endpoint | 
			MACE | 
		 
	
	 
	
	
	
	
	
	
	
  
	Results	
	
	
	
		
	
	
		
			Endpoint
		
	
	
		
		Studied treat. n/N
			
	
	
		
		Control treat. n/N
		
	
	
		
			Graph
		
	
	
		
			RR [95% CI]
		
	
	
		
			
				
				MACE
				 
			
		
		
			
			
		
	
	
		
			
				
				MI (fatal and non fatal)
				 
			
		
		
			
			
		
	
	
		
			
				
				target lesion revascularisation 
				 
			
		
		
			
			
		
	
	
		
			
				
				4y stent thrombosis (ARC)
				 
			
		
			
				
				3 / 50 
				
			
			
				
				0 / 50 
				
			
		
			
				
					
						classic
					
					
					
				
			
			
			
		
			
				
					13,00 [0,23;745,45]
				
			
	
	
		
		
		
		
		
			
				0
			
		
		
		
		
		
				2
		
		
		
		
		
			1.0
		
	
  
 
	 
		
	
		
		
				
					| 
						Relative risks
					 | 
				 
			
			| Endpoint | 
			Events (%) | 
			Relative Risk | 
			95% CI | 
			Endpoint definition in the trial | 
			Ref | 
			 
			
			| Studied treat. | 
			Control treat. | 
			 
					
					
					
					
					
					
					
					
					
					
					
					
					
						| 
							4y stent thrombosis (ARC)
						 | 
						3 / 50 (6,0%) | 
						0 / 50 (1,0%) | 
						6,00 | 
						[0,31;116,74] | 
						 | 
						 | 
					 
					
					
					
					
					
					
					
					
					
		
			| 
			The primary endpoint (if exists) appears in blod characters
			 | 
		 
		
			| 
			Reference(s) used for data extraction: 
			 | 
		 
		 
		
		
			
			| Endpoint | 
			studied treat. | 
			control treat. | 
			mean diff | 
			 
		 
	 
	
	
	
				
					| 
						Absolute risk reduction 
					 | 
				 
	
		| Endpoint | 
		Events rate | 
		Absolute risk reduction (ARR) | 
	 
	
		| Studied treat. | 
		Control treat. | 
	 
	 	
	 
Meta-analysis of all similar trials: 
			
				
					Drug eluting stent in coronary artery disease for acute myocardial infarction
				
			 
			
				
					Drug eluting stent in coronary artery disease for all type of patients
				
			 
	
  
	
	
	
	
	
	
	
	
	
	
	
		 
		Reference(s)
	
	
	
			- 
				
			    Cervinka . 
			    A Randomized Comparison of Genous Stent Versus Chromium-Cobalt Stent for Treatment of ST-Elevation Myocardial Infarction: A 6-Month Clinical, Angiographic, and IVUS Follow-up: GENIUS-STEMI trial.
			    ACC.09/i2, Orlando, FL, March 2009
			    
 
				
					 
					Pubmed
				 
				|
				
					Hubmed
				
				| Fulltext
		 
		
	 	
			 
			
 |